Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609552 | 0.91 | PDE4B (0.42) | GPR119PDE4BCHRM2 | |
| SCHEMBL611813 | 0.86 | GPR119 (0.41) | GPR119PDE4BFAAH | |
| SCHEMBL10058391 | 0.85 | GPR119 (0.40) | GPR119PDE4BCHRM2 | |
| SCHEMBL13186587 | 0.84 | GPR119 (0.42) | GPR119PDE4BFAAH | |
| SCHEMBL2181628 | 0.80 | GPR119 (0.44) | GPR119PDE4BCHRM2FAAH | |
| SCHEMBL610301 | 0.80 | GPR119 (0.38) | GPR119PDE4BFAAH | |
| SCHEMBL10058398 | 0.77 | PDE4B (0.39) | GPR119PDE4B | |
| SCHEMBL611471 | 0.77 | GPR119 (0.41) | GPR119 | |
| SCHEMBL611472 | 0.77 | GPR119 (0.41) | GPR119 | |
| SCHEMBL608827 | 0.77 | PDE4B (0.40) | GPR119PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-2406256-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103335-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103335-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | GPR119 1/4885PDE4B 451/4885GAA 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.